Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan. [PDF]
Noto S +7 more
europepmc +1 more source
A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan. [PDF]
Haleem AA +6 more
europepmc +1 more source
Neutralizing Antiviral Antibodies Reduce Hematogenic Viral Spread but Not Antiviral Cytotoxic T Cell Induction and Subsequent Immunopathology [PDF]
Battegay, Manuel +4 more
core
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants. [PDF]
Goh DYT +8 more
europepmc +1 more source
Prevention of respiratory syncytial virus disease by immunisation. [PDF]
Benzaken TR, Watson C, Drysdale SB.
europepmc +1 more source
Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants. [PDF]
Calomfirescu-Avramescu A +4 more
europepmc +1 more source
Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants. [PDF]
Shin T +4 more
europepmc +1 more source
Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing. [PDF]
Tsukahara M +4 more
europepmc +1 more source
Related searches:

